PMID- 34562237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230921
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 11
DP  - 2021 Nov
TI  - Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the 
      SURE UK Multicentre, Prospective, Observational Study.
PG  - 2891-2905
LID - 10.1007/s13300-021-01141-8 [doi]
AB  - INTRODUCTION: Once-weekly (OW) semaglutide was associated with clinically 
      relevant improvements in glycaemic control and body weight versus comparators in 
      the SUSTAIN randomised controlled trials (RCTs). SURE UK, which is one of a 
      series of individual studies that comprise the SURE programme, evaluated the use 
      of OW semaglutide in a real-world patient population with type 2 diabetes (T2D) 
      in the UK. METHODS: In this prospective, observational study, adults (>/= 18 years) 
      with >/= 1 documented glycated haemoglobin (HbA(1c)) value </= 12 weeks before 
      semaglutide initiation were enrolled. The primary endpoint was change in HbA(1c) 
      from baseline to end of study (EOS; ~ 30 weeks, although due to the COVID-19 
      pandemic, visits up to week 52 were permitted). Secondary endpoints included 
      change in body weight, waist circumference and patient-reported outcomes (PROs). 
      Physicians were to report all episodes of documented or severe hypoglycaemia, 
      fatal events, serious adverse drug reactions, pregnancies and adverse events 
      (AEs) in foetuses/newborn infants; other AEs during the study period could be 
      reported on a voluntary basis. RESULT: The estimated mean change in HbA(1c) from 
      baseline to EOS was - 16.3 mmol/mol [95% confidence interval (CI): - 18.22, - 
      14.37] (- 1.5%-points [95% CI - 1.67, - 1.31]; p < 0.0001) among the 171 enrolled 
      patients who completed the study on treatment. Mean body weight change was - 
      5.8 kg (95% CI - 6.75, - 4.94; p < 0.0001). Sensitivity analyses showed similar 
      results. Improvements were also observed in other secondary endpoints, including 
      PROs. No new safety concerns were identified with semaglutide treatment. 
      CONCLUSION: Patients receiving OW semaglutide experienced statistically 
      significant and clinically relevant reductions from baseline in HbA(1c) and body 
      weight. These results are in line with those of the SUSTAIN RCTs and support the 
      use of OW semaglutide in routine clinical practice in adults with T2D in the UK. 
      TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03876015.
CI  - (c) 2021. The Author(s).
FAU - Holmes, Patrick
AU  - Holmes P
AUID- ORCID: 0000-0002-6401-663X
AD  - St George's Medical Practice, Yarm Road, Darlington, DL2 1BY, UK. 
      patrickholmes@nhs.net.
FAU - Bell, Heather Elizabeth
AU  - Bell HE
AD  - Old School Surgery, Greenisland, Northern Ireland, UK.
FAU - Bozkurt, Karan
AU  - Bozkurt K
AD  - Novo Nordisk Ltd, London, UK.
FAU - Catarig, Andrei-Mircea
AU  - Catarig AM
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Clark, Alice
AU  - Clark A
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Machell, Alena
AU  - Machell A
AD  - Egremont Medical Centre, Wallasey, UK.
FAU - Sathyapalan, Thozhukat
AU  - Sathyapalan T
AD  - Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, 
      University of Hull, Hull, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03876015
PT  - Journal Article
DEP - 20210925
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8475854
OTO - NOTNLM
OT  - Glucagon-like peptide-1 receptor agonist
OT  - Real-world evidence
OT  - Semaglutide
OT  - Type 2 diabetes
EDAT- 2021/09/26 06:00
MHDA- 2021/09/26 06:01
PMCR- 2021/09/25
CRDT- 2021/09/25 12:11
PHST- 2021/06/18 00:00 [received]
PHST- 2021/08/09 00:00 [accepted]
PHST- 2021/09/26 06:00 [pubmed]
PHST- 2021/09/26 06:01 [medline]
PHST- 2021/09/25 12:11 [entrez]
PHST- 2021/09/25 00:00 [pmc-release]
AID - 10.1007/s13300-021-01141-8 [pii]
AID - 1141 [pii]
AID - 10.1007/s13300-021-01141-8 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Nov;12(11):2891-2905. doi: 10.1007/s13300-021-01141-8. Epub 
      2021 Sep 25.